logo
Share SHARE
FONT-SIZE Plus   Neg

Georgia Gulf Says Remains Focused On Executing Its Strategy - Quick Facts

Georgia Gulf Corp. (GGC) issued a statement regarding Westlake Chemical Corp.'s (WLK) announcement that it has withdrawn its previously disclosed unsolicited proposal to acquire Georgia Gulf.

In the statement, Georgia Gulf said it remains focused on executing its strategy and is confident that it is well positioned to create significant value for its stockholders.

"As recently announced, the Company's first quarter 2012 operating results were the best Georgia Gulf has reported for the first quarter in the past six years, which demonstrates our ability to generate stockholder value even in a period of volatile macroeconomic conditions and a slow housing market," said Paul Carrico, President and Chief Executive Officer.

Earlier today Westlake Chemical said that it has withdrawn its unsolicited proposal to acquire Georgia Gulf following talks with the smaller rival's management.

Westlake also said it now plans to sell its stake in Georgia Gulf stock as "market conditions permit". Westlake holds about 4.8 percent of Georgia Gulf's outstanding shares.

The latest development follows Georgia Gulf's rejection of a sweetened $35 a share offer from Westlake in February.

On February 1, Westlake lifted its offer to acquire all the shares of Georgia Gulf to $35 a share. It was $5 more than the initial bid of $30 offered by the Houston, Texas-based Westlake on January 13. The sweetened offer represented a 43 percent premium to Georgia Gulf's closing stock price of $24.48 on January 12.

Westlake had first made the offer on September 30, but publicly disclosed it only on January 13 because of continued rejection of the offer and unwillingness to engage in substantive discussions by Georgia Gulf.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Rare commodities are worth more than good is a Chinese adage. And more so when it is in the sought-after drug space. Rare and ultra-rare diseases, also called orphan and ultra-orphan diseases, as the names imply, affect very small numbers of patients. So why the clamor? Shares of steel giant ArcelorMittal were losing around 4 percent in the early morning trading in Amsterdam after the company reported sharp decline in first-quarter EBITDA, a key earnings metric, as sales were weak with lower prices and production. Net loss, however, narrowed from last year. The company also confirmed its forecast for annual EBITDA, which is lower than last year. As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term?
comments powered by Disqus
Follow RTT